(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A definitive Manual for the Over-Ear Earphones - 27 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- 3US FDA unveils new pathway to approve personalized therapies
- 4Manual for Tracking down the Mysterious Cascades in China
- 5Partake in the Outside: Senior-Accommodating Exercises for 2024
- Top Music and Dance Celebration: Which One Gets You Going?
- A definitive Manual for Good dieting on a Tight spending plan
- Favored Chinese Dish: Make Your Determination
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- The Solution to Ecological Protection: Saving Nature for People in the future
- Wedding trip Objections in the US
- Best Streaming Gadget for Your Home Theater
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- Opening Innovativeness: Moving Thoughts and Tasks
